Manufacturer
NOVARTIS PHARMA STEIN AG
Contents
Nilotinib
Indication
Chronic phase Philadelphia chromosome positive chronic myelogenous leukaemia, Accelerated phase Philadelphia chromosome positive chronic myelogenous leukaemia, Chronic phase Philadelphia chromosome positive chronic myelogenous leukaemia
Instruction
Should be taken on an empty stomach. Avoid food at least 2 hr before & at least 1 hr after a dose. Swallow whole do not chew/crush. Avoid grapefruit products.
Drug interaction
May decrease nilotinib efficacy with PPIs.Potentially Fatal: Concomitant use with potent CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, voriconazole, ritonavir, clarithromycin, telithromycin) may increase nilotinib serum concentrations. Antiarrhythmics (e.g. amiodarone, disopyramide, procainamide, quinidine, sotalol) and other QT prolonging drugs (e.g. chloroquine, halofantrine, clarithromycin, haloperidol, methadone and moxifloxacin) may increase the risk of prolonged QT interval. Concomitant use with CYP3A4 inducers (e.g. rifampicin, phenobarbital, carbamazepine, phenytoin) may decrease nilotinib serum concentrations.
Malaysia
